Quarterly ResultMay 13, 2026, 04:02 PM
vTv Therapeutics Q1 Net Income $24.1M; CATT1 Enrollment on Track
AI Summary
vTv Therapeutics reported strong financial results for Q1 2026, with a net income of $24.1 million, a significant improvement from a net loss in the prior year. The company's cash position was bolstered to $98.1 million, primarily due to a $20.0 million upfront payment from a license amendment with Newsoara Biopharma. Enrollment for the Phase 3 CATT1 trial of cadisegliatin remains on track for completion in the third quarter of 2026, with current cash expected to fund operations through the anticipated topline data readout.
Key Highlights
- Q1 2026 net income $24.1M ($1.94 basic EPS) vs. Q1 2025 net loss $5.1M ($0.77 basic EPS).
- Cash and cash equivalents $98.1M as of March 31, 2026, up from $88.9M on Dec 31, 2025.
- Received $20.0M upfront payment from Newsoara Biopharma license amendment for HPP737.
- Eligible for up to $115.0M in development and sales milestones from Newsoara deal.
- Phase 3 CATT1 trial enrollment for cadisegliatin on track for completion in Q3 2026.
- R&D expenses rose to $9.0M in Q1 2026 from $2.8M in Q1 2025 due to CATT1 trial.